MA62176A1 - Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène - Google Patents

Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène

Info

Publication number
MA62176A1
MA62176A1 MA62176A MA62176A MA62176A1 MA 62176 A1 MA62176 A1 MA 62176A1 MA 62176 A MA62176 A MA 62176A MA 62176 A MA62176 A MA 62176A MA 62176 A1 MA62176 A1 MA 62176A1
Authority
MA
Morocco
Prior art keywords
ibuprofen
pharmaceutical composition
composition containing
acetominophen
containing acetominophen
Prior art date
Application number
MA62176A
Other languages
English (en)
Other versions
MA62176B1 (fr
Inventor
Matt Callahan
Maura Murphy
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of MA62176A1 publication Critical patent/MA62176A1/fr
Publication of MA62176B1 publication Critical patent/MA62176B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formes posologiques orales solides contenant 325 mg d'acétaminophène et 97,5 mg d'ibuprofène ou 500 mg d'acétaminophène et 150 mg d'ibuprofène, l'ibuprofène ayant un [d50] compris entre 1 et 9 µm.
MA62176A 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène MA62176B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/287,836 US11197830B2 (en) 2019-02-27 2019-02-27 Pharmaceutical composition containing acetaminophen and ibuprofen
PCT/US2020/020112 WO2020176736A1 (fr) 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène

Publications (2)

Publication Number Publication Date
MA62176A1 true MA62176A1 (fr) 2024-01-31
MA62176B1 MA62176B1 (fr) 2025-10-31

Family

ID=72140141

Family Applications (2)

Application Number Title Priority Date Filing Date
MA62176A MA62176B1 (fr) 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène
MA54028A MA54028B2 (fr) 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA54028A MA54028B2 (fr) 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène

Country Status (26)

Country Link
US (5) US11197830B2 (fr)
EP (2) EP4438121A3 (fr)
CN (2) CN113795243A (fr)
AU (4) AU2019268077B2 (fr)
BR (1) BR112021017037A2 (fr)
CA (1) CA3131917A1 (fr)
CL (1) CL2021002252A1 (fr)
CO (1) CO2021011525A2 (fr)
CR (1) CR20210451A (fr)
EA (1) EA202192118A1 (fr)
EC (1) ECSP21072036A (fr)
GB (1) GB2595406B (fr)
IL (1) IL285866A (fr)
JO (1) JOP20210235A1 (fr)
MA (2) MA62176B1 (fr)
MX (2) MX2021010338A (fr)
MY (1) MY206658A (fr)
NZ (1) NZ759337A (fr)
PE (1) PE20220591A1 (fr)
PH (1) PH12021552068A1 (fr)
SG (1) SG11202109258WA (fr)
TN (1) TN2021000176A1 (fr)
TW (1) TW202045148A (fr)
UA (1) UA127775C2 (fr)
WO (1) WO2020176736A1 (fr)
ZA (1) ZA202407049B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
BR112021026407A8 (pt) * 2019-06-27 2022-11-22 Pf Consumer Healthcare 1 Llc Composição de ibuprofeno e acetaminofeno

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5148139B2 (fr) 1972-09-30 1976-12-18
JPS5148139U (fr) 1974-10-08 1976-04-10
JPS5830412Y2 (ja) 1976-01-10 1983-07-05 株式会社クボタ 収穫機の茎葉切断装置
AU605538B2 (en) 1988-01-19 1991-01-17 Adcock Ingram Limited Pharmaceutical unit
CA1336687C (fr) 1989-08-23 1995-08-15 Thomas M. Tencza Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5260337A (en) 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
JP3982889B2 (ja) 1997-11-28 2007-09-26 あすか製薬株式会社 イブプロフェン含有医薬製剤
US6440983B1 (en) 2000-12-21 2002-08-27 Mary Theresa Frank-Kollman Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
GB0414442D0 (en) 2004-06-28 2004-07-28 Borealis As Zeolite catalysts
PL1781277T3 (pl) * 2004-07-07 2012-07-31 Aft Pharmaceuticals Ltd Kompozycja łączona zawierająca ibuprofen i paracetamol
KR20060072839A (ko) 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
GB0519350D0 (en) 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
WO2008079818A2 (fr) 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Administration intraveineuse de formulations analgésiques hydrosolubles
JP5148139B2 (ja) 2007-03-12 2013-02-20 パナソニック株式会社 半導体装置及びその製造方法
CA2731801C (fr) * 2007-07-23 2013-11-26 Kingsway Pharmaceuticals Inc. Formulations therapeutiques pour le traitement de symptomes apparentes au rhume et a la grippe
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
TR201102810T2 (tr) 2008-10-14 2011-05-23 Aft Pharmaceuticals Limited Tıbbi bir ürün ve tedavi
MA33293B1 (fr) 2009-04-24 2012-05-02 Iceutica Pty Ltd Procédé d'amélioration du profil de dissolution d'une matière biologiquement active
BRPI1014275B8 (pt) 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
US11135188B2 (en) * 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
MY164112A (en) 2010-07-07 2017-11-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
CL2010000738A1 (es) 2010-07-08 2011-03-25 Wockhardt Res Centre Suspension farmaceutica oral que comprende desde 100 hasta 500 mg/5ml de paracetamol, desde 40 hasta 80 mg/5ml de ibuprofeno o desde 200 hasta 400 mg/5ml de paracetamol, desde 100 hasta 200 mg/5ml de ibuprofeno y uno o mas excipientes farmaceuticamente aceptables, util para tratar el dolor pre, peri o postoperatorio.
MY160572A (en) * 2010-11-04 2017-03-15 Aft Pharmaceuticals Ltd A combination composition
JP5830412B2 (ja) 2011-03-02 2015-12-09 ライオン株式会社 水難溶性薬物と賦形剤との粉砕物の製造方法、造粒粒子の製造方法、錠剤の製造方法
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine

Also Published As

Publication number Publication date
AU2021200634A1 (en) 2021-03-04
GB2595406B (en) 2023-05-10
EP4438121A2 (fr) 2024-10-02
JOP20210235A1 (ar) 2023-01-30
US20240091160A1 (en) 2024-03-21
US12194151B2 (en) 2025-01-14
WO2020176736A1 (fr) 2020-09-03
AU2019268077A1 (en) 2020-09-10
CN113795243A (zh) 2021-12-14
CO2021011525A2 (es) 2021-09-20
EA202192118A1 (ru) 2021-11-18
ZA202407049B (en) 2026-02-25
TW202045148A (zh) 2020-12-16
CA3131917A1 (fr) 2020-09-03
EP3930691A4 (fr) 2022-11-30
MA54028A1 (fr) 2022-06-30
MA54028B2 (fr) 2023-10-31
US20250213490A1 (en) 2025-07-03
NZ759337A (en) 2023-06-30
CR20210451A (es) 2021-12-02
AU2021200634B2 (en) 2022-03-10
MA62176B1 (fr) 2025-10-31
MY206658A (en) 2024-12-31
MX2021010338A (es) 2022-01-07
AU2019268077B2 (en) 2021-02-25
IL285866A (en) 2021-10-31
PE20220591A1 (es) 2022-04-22
EP4438121A3 (fr) 2024-12-18
US20230201125A1 (en) 2023-06-29
UA127775C2 (uk) 2023-12-27
TN2021000176A1 (en) 2023-04-04
US11534407B2 (en) 2022-12-27
ECSP21072036A (es) 2021-11-30
EP3930691B1 (fr) 2026-03-11
CL2021002252A1 (es) 2022-04-29
AU2024203208A1 (en) 2024-05-30
AU2022201196A1 (en) 2022-03-17
BR112021017037A2 (pt) 2021-11-09
US20220175680A1 (en) 2022-06-09
EP3930691A1 (fr) 2022-01-05
GB202112205D0 (en) 2021-10-13
GB2595406A (en) 2021-11-24
US11872317B2 (en) 2024-01-16
US20200268673A1 (en) 2020-08-27
MX2024009106A (es) 2024-07-30
PH12021552068A1 (en) 2022-06-06
CN119055604A (zh) 2024-12-03
SG11202109258WA (en) 2021-09-29
US11197830B2 (en) 2021-12-14

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
WO2003103603A3 (fr) Nouveau sel de type formiate de o-desmethylvenlafaxine
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
WO2007016563A3 (fr) Formulations pharmaceutiques resistantes a l'alcool
WO2005034908A3 (fr) Forme posologique solide comprenant une fibrate et une statine
BR0213355A (pt) composições farmacêuticas
MA31706B1 (fr) Formulations galéniques de composés organiques
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
MA27115A1 (fr) Sel de perindopril et les compositions pharmaceutiques qui les contiennent
ZA202407049B (en) Pharmaceutical composition containing acetominophen and ibuprofen
BR0111868A (pt) Composições farmacêuticas
EP4371614A3 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
EA200701221A1 (ru) Режим применения кладрибина для лечения рассеянного склероза
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
MA56341B1 (fr) Combinaison d'ibuprofène et de tramadol pour soulager la douleur
BRPI0416691A (pt) forma de preparação farmacêutica sólida
MA38093A1 (fr) Formulations à libération modifiée pour l'oprozomib
FR3083980B1 (fr) Composition pharmaceutique sous la forme d'un comprime a croquer de diosmine ou d'une fraction flavonoique